Evidence map›Paper›PMID 27504605›Full record

Trial reportCancer epidemiology2016

Inflammatory biomarkers, aspirin, and risk of colorectal cancer: Findings from the physicians' health study.

Chul Kim, Xuehong Zhang, Andrew T Chan, Howard D Sesso, Nader Rifai, Meir J Stampfer, Jing Ma

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer epidemiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Chul KimDepartment of Medicine, University of Minnesota Medical School, Minneapolis, MN, United States; Medical Oncology Service, National Cancer Institute, National Institute of Health, Bethesda, MD, United States. Electronic address: kimc5@mail.nih.gov.
Xuehong ZhangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Andrew T ChanChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States; Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Howard D SessoDepartment of Epidemiology, Harvard School of Public Health, Boston, MA, United States; Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
Nader RifaiDepartment of Pathology, Children's Hospital Medical Center, Boston, MA, United States.
Meir J StampferChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States; Department of Epidemiology, Harvard School of Public Health, Boston, MA, United States; Department of Nutrition, Harvard School of Public Health, Boston, MA, United States.
Jing MaChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States. Electronic address: jing.ma@channing.harvard.edu.
Harvard University · USBrigham and Women's Hospital · USUniversity of Minnesota Medical Center · US

Funding

Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI TWOROGER, SHELLEY S · 2000 to 2019
$77.8M
Physicians' Health Study II: Prevention Trial of VitaminsR01CA097193 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GAZIANO, J. MICHAEL · 2002 to 2011
$15.7M
Sleep Duration, Childhood Energy Balance, and Insulin Resistance in AdolescenceU54CA155626 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI TAVERAS BENAVIDEZ, ELSIE MIREYA · 2011 to 2015
$9.6M
Inflammation and Colorectal NeoplasiaR01CA137178 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHAN, ANDREW T · 2009 to 2019
$6.5M
NUTRITIONAL BIOCHEMISTRY MARKERS OF CANCER AND MIR01CA042182 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI MA, JING · 1986 to 2007
$5.3M
TRIAL OF ASPIRIN AND BETA-CAROTENE IN U S MD'SR01HL034595 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E · 1985 to 1991
–
NCI NIH HHS P01 CA087969NCI NIH HHS R01 CA042182NCI NIH HHS R01 CA097193NCI NIH HHS R01 CA137178NCI NIH HHS U54 CA155626NHLBI NIH HHS R01 HL026490NHLBI NIH HHS R01 HL034595
6 · The paper itself

Abstract

backgroundChronic inflammation has been implicated in colorectal carcinogenesis. However, the associations between plasma inflammatory markers and risk of colorectal cancer have been inconsistent.

methodsIn a nested case-control study in the Physicians' Health Study, we prospectively investigated the associations of plasma C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor receptor 2 (TNFR-2) with risk of colorectal cancer, and whether aspirin modified these associations among 268 colorectal cancer patients and 446 age- and smoking-matched controls.

resultsIn multivariate-adjusted models, plasma levels of CRP, IL-6 and TNFR-2 were not significantly associated with risk of colorectal cancer, although a positive trend was observed for TNFR-2 (RR

conclusionPlasma inflammatory markers were not significantly associated with colorectal cancer risk among men, though there was a statistically non-significant positive trend between TNFR-2 and colorectal cancer risk. More studies are required to understand the relationship between the role of TNFα pathway, aspirin, and colorectal cancer risk.

Indexed as

AdultAgedAged, 80 and overAspirinCase-Control StudiesColorectal NeoplasmsC-Reactive ProteinDouble-Blind MethodFemaleHumansInflammationInterleukin-6MaleMiddle AgedProspective StudiesReceptors, Tumor Necrosis Factor, Type IIAspirinC-Reactive ProteinIL6 protein, humanInterleukin-6Receptors, Tumor Necrosis Factor, Type IIAspirinColorectal cancerCRPIL-6TNFR-2

Identifiers

PMID27504605
PMCPMC5821121
OpenAlexW2506544421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.